Stories

SaveSave story

Celgene buying cancer drug startup for up to $7 billion

ccPixs.com / Flickr Creative Commons

Celgene on Monday said that it has agreed to acquire cancer drug startup Impact Biomedicines for upwards of $7 billion.

Why it matters: Because this is a silly stupendous return on investment for Medicxi Ventures, which was the sole participant in Impact's $22.5 million Series A funding round.